[1] 毕增祺,李学旺,何祖根, 等. IgA 肾病 40例临床病理分析[J]. 中华内科杂志, 1984,23(2):136-139. [2] Berger J,Hinglais N. Les Depots intercapillaires d'IgA-IgG [J]. J Urol,1968,73: 694-695. [3] Li L S, Liu Z H. Epidemiologic data of renal diseases from a single unit in China: analysis based on 13 519 renal biopsies [J]. Kidney Int, 2004, 66(3): 920-923. [4] Geddes C C, Rauta V, Gronhagen-Riska C, et al. A tricontinental view of IgA nephropathy [J]. Nephrol Dial Transplant, 2003, 18(8): 1541-1548. [5] Donadio J V, Grande J P. IgA nephropathy[J]. N Engl J Med, 2002,347: 738-745. [6] Rifai A, Millard K. Glomerular deposition of immune complexes prepared with monomeric or polymeric IgA[J].Clin Exp Immunol,1985, 60(2):363-368 [7] Cuevas X, Lloveras J, Mir M, et al. Disappearance of mesangial IgA deposits from the kidneys of two donors after transplantation[J]. Transplant Proc, 1987, 19 (1 Pt 3): 2208-2209. [8] Alamartine E, Sabatier J C, Berthoux F C. Comparison of pathological lesions on repeated renal biopsies in 73 patients with primary IgA glomerulonephritis: value of quantitative scoring and approach to final prognosis [J]. Clin Nephrol, 1990, 34(2): 41-45. [9] Maschio G, Cagnoli L, Claroni F, et al. ACE inhibition reduces proteinuria in normotensive patients with IgA nephropathy: a multicentre, randomized, placebo-controlled study[J]. Nephrol Dial Transplant, 1994, 9(3): 265-269. [10] James P A, Oparil S, Barry L. et al. 2014 evidence-based guideline for the management of high blood pressure in adults[J]. JAMA, 2013, 311(5): 507-520. [11] Syrjanen J, Mustonen J, Pasternack A. Hypertriglyceridaemia and heperuricaemia are risk factor for progression of IgA nephropathy [J]. Nephrol Dial Transplant, 2000, 15(1): 34-42. [12] Liu Y, Liu H, Tu X, et al. Study of tonsillectomy for IgA nephropathy patients: short- and longer-term observation[J]. Int Urol Nephrol, 2013, 23(11): 982-986.
PDF(896 KB)
